No Data
No Data
Biodexa BDRX +52% Phase 2 Data; OKYO Pharma OKYO +26% Phase 2 Trial Plans
H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for OKYO Pharma on Promising Clinical Results of OK-101 for Neuropathic Corneal Pain
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Express News | OKYO Pharma Shares Are Trading Higher After the Company Announced Plan to Advance OK-101 Into a Phase 2 Clinical Trial of Neuropathic Corneal Pain
OKYO Pharma Advances OK-101 Into Phase 2 Trials
No Data